MCID: OPT003
MIFTS: 50

Opiate Dependence

Categories: Mental diseases

Aliases & Classifications for Opiate Dependence

MalaCards integrated aliases for Opiate Dependence:

Name: Opiate Dependence 12 15
Opioid Dependence 74 54 17
Opioid-Related Disorders 71
Opioid Type Dependence 12
Opiate Addiction 71

Classifications:



External Ids:

Disease Ontology 12 DOID:2559
ICD9CM 34 304.0 304.00
MeSH 43 D009293
SNOMED-CT 67 75544000
ICD10 32 F11.2
UMLS 71 C0027412 C0524662

Summaries for Opiate Dependence

Disease Ontology : 12 A drug dependence that involves the continued use of opiate drugs despite despite problems related to use of the substance.

MalaCards based summary : Opiate Dependence, also known as opioid dependence, is related to opioid dependence 1 and opioid addiction. An important gene associated with Opiate Dependence is ODS1 (Opioid Dependence, Susceptibility To, 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Valproic acid and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and pituitary, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 74 Opioid use disorder is a pattern of opioid use that causes significant impairment or distress. Symptoms... more...

Related Diseases for Opiate Dependence

Diseases related to Opiate Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 226)
# Related Disease Score Top Affiliating Genes
1 opioid dependence 1 34.7 OPRM1 ODS1
2 opioid addiction 32.8 OPRM1 OPRK1 OPRD1 DRD2
3 heroin dependence 31.8 SLC6A4 PDYN OPRM1 OPRD1 DRD3 DRD2
4 morphine dependence 31.6 PDYN OPRM1 OPRL1 OPRK1 OPRD1 FOS
5 avoidant personality disorder 30.6 TPH1 SLC6A4 DRD3 DRD2
6 polysubstance abuse 30.5 DRD3 DRD2
7 sexual disorder 30.5 SLC6A4 POMC DRD2
8 social phobia 30.3 SLC6A4 LOC110806262 DRD2
9 mental depression 30.3 TPH1 SLC6A4 POMC DRD2 CREB1
10 neonatal abstinence syndrome 30.3 OPRM1 OPRL1 OPRK1 OPRD1
11 generalized anxiety disorder 30.2 TPH1 SLC6A4 DRD2
12 cocaine abuse 30.1 SLC6A4 OPRK1 NGF DRD3 DRD2
13 antisocial personality disorder 30.1 SLC6A4 LOC110806262 DRD2 ANKK1
14 schizoaffective disorder 30.1 SLC6A4 DRD3 DRD2
15 obsessive-compulsive personality disorder 30.1 SLC6A4 DRD3
16 personality disorder 30.1 TPH1 TH SLC6A4 DRD3 DRD2 ANKK1
17 conduct disorder 30.0 TPH1 SLC6A4 POMC DRD2
18 borderline personality disorder 30.0 TPH1 TH SLC6A4 DRD2
19 diarrhea 30.0 SLC6A4 POMC OPRM1 OPRK1
20 restless legs syndrome 30.0 TH SLC6A4 POMC DRD3 DRD2
21 alcohol use disorder 29.9 SLC6A4 OPRM1 DRD3 DRD2 CREB1 ANKK1
22 post-traumatic stress disorder 29.8 SLC6A4 POMC FOS DRD2
23 substance abuse 29.8 SLC6A4 PDYN OPRM1 OPRL1 OPRK1 OPRD1
24 alexithymia 29.8 SLC6A4 LOC110806262 DRD2 ANKK1
25 sleep disorder 29.7 TH SLC6A4 POMC IGF1 FOS DRD2
26 panic disorder 29.7 TPH1 SLC6A4 POMC OPRL1 DRD3 DRD2
27 eating disorder 29.7 SLC6A4 POMC OPRM1 DRD3 DRD2 ANKK1
28 major depressive disorder 29.5 TPH1 SLC6A4 POMC OPRM1 NGF DRD3
29 neuroblastoma 29.5 TH OPRM1 NGF IGF1 FOS CREB1
30 mood disorder 29.5 TPH1 TH SLC6A4 POMC DRD3 DRD2
31 trigeminal neuralgia 29.3 SLC6A4 OPRM1 OPRL1 OPRK1 OPRD1 LOC110806262
32 tobacco addiction 29.3 TPH1 SLC6A4 PDYN OPRM1 DRD3 DRD2
33 psychotic disorder 29.3 TPH1 TH SLC6A4 PDYN OPRM1 DRD3
34 somatoform disorder 29.3 TPH1 SLC6A4 OPRM1 OPRL1 OPRD1 NGF
35 obsessive-compulsive disorder 29.2 TPH1 SLC6A4 POMC PDYN IGF1 DRD3
36 drug dependence 29.1 SLC6A4 POMC PDYN OPRM1 OPRL1 OPRK1
37 constipation 29.1 TH SLC6A4 PDYN OPRM1 OPRL1 OPRK1
38 cocaine dependence 28.9 SLC6A4 POMC PDYN OPRM1 OPRK1 OPRD1
39 substance dependence 28.9 TPH1 SLC6A4 POMC PDYN OPRM1 OPRK1
40 attention deficit-hyperactivity disorder 28.9 TPH1 TH SLC6A4 OPRM1 NGF FOS
41 withdrawal disorder 28.9 POMC PDYN OPRM1 OPRL1 OPRK1 OPRD1
42 bipolar disorder 28.7 TPH1 TH SLC6A4 PDYN NGF IGF1
43 pain agnosia 28.6 POMC PDYN OPRM1 OPRL1 OPRK1 OPRD1
44 opioid abuse 28.5 PDYN OPRM1 OPRL1 OPRK1 OPRD1 NPFF
45 anxiety 28.1 TPH1 TH SLC6A4 POMC PDYN OPRM1
46 alcohol dependence 28.1 TPH1 TH SLC6A4 POMC PDYN OPRM1
47 migraine with or without aura 1 27.9 TPH1 SLC6A4 POMC OPRM1 OPRL1 OPRK1
48 schizophrenia 27.6 TPH1 TH SLC6A4 POMC PDYN OPRM1
49 disease of mental health 27.4 TH SLC6A4 POMC PDYN OPRM1 OPRL1
50 barbiturate dependence 10.5 TPH1 SLC6A4

Graphical network of the top 20 diseases related to Opiate Dependence:



Diseases related to Opiate Dependence

Symptoms & Phenotypes for Opiate Dependence

MGI Mouse Phenotypes related to Opiate Dependence:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.31 CREB1 DRD2 DRD3 FOS NGF NPFF
2 homeostasis/metabolism MP:0005376 10.2 CREB1 DRD2 DRD3 FOS IGF1 NGF
3 growth/size/body region MP:0005378 10.15 CREB1 DRD2 DRD3 FOS IGF1 NGF
4 integument MP:0010771 10.07 DRD2 FOS IGF1 NGF OPRD1 OPRK1
5 adipose tissue MP:0005375 10.06 DRD2 DRD3 FOS IGF1 OPRM1 PDYN
6 endocrine/exocrine gland MP:0005379 10.06 CREB1 DRD2 FOS IGF1 OPRK1 OPRM1
7 nervous system MP:0003631 10 CREB1 DRD2 DRD3 FOS IGF1 NGF
8 no phenotypic analysis MP:0003012 9.5 DRD2 NGF OPRD1 OPRM1 PDYN POMC
9 normal MP:0002873 9.32 CREB1 DRD2 FOS IGF1 KPNA3 NGF

Drugs & Therapeutics for Opiate Dependence

Drugs for Opiate Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 326)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
2
Ribavirin Approved Phase 4 36791-04-5 37542
3
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
5
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
6
Norepinephrine Approved Phase 4 51-41-2 439260
7
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
8
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
9
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
10
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
11
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
12
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
13
Tapentadol Approved Phase 4 175591-23-8 9838022
14
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
15
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
16
Cobicistat Approved Phase 4 1004316-88-4
17
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
18
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
19
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
20
Nicotine Approved Phase 4 54-11-5 942 89594
21
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
22
Menthol Approved Phase 4 2216-51-5 16666
23
Methadone Approved Phase 4 76-99-3 4095
24
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
25
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
26
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
27
Methadyl Acetate Experimental, Illicit Phase 4 509-74-0 10517
28
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
29 Adrenergic alpha-2 Receptor Agonists Phase 4
30 Adrenergic Agonists Phase 4
31 Anesthetics, General Phase 4
32 Anesthetics, Intravenous Phase 4
33 GABA Agents Phase 4
34 Interferon alpha-2 Phase 4
35 Interferon-alpha Phase 4
36 Immunologic Factors Phase 4
37 Hypnotics and Sedatives Phase 4
38 Desvenlafaxine Succinate Phase 4 386750-22-7
39 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
40 Ketorolac Tromethamine Phase 4
41 Adrenergic Agents Phase 4
42 Excitatory Amino Acid Antagonists Phase 4
43 Excitatory Amino Acids Phase 4
44 Hormones Phase 4
45 Tranquilizing Agents Phase 4
46 calcium channel blockers Phase 4
47 Calcium, Dietary Phase 4
48 Anticonvulsants Phase 4
49 Psychotropic Drugs Phase 4
50 Cytochrome P-450 Enzyme Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 709)
# Name Status NCT ID Phase Drugs
1 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
2 SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model Unknown status NCT00241930 Phase 4
3 Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study Completed NCT00015340 Phase 4 Buprenorphine/naloxone
4 An Open Multi-center Trial of Suboxone® (Buprenorphine/Naloxone) Treatment Among Opiate-Dependent Subjects Completed NCT00901875 Phase 4 Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
5 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
6 Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study) Completed NCT00263458 Phase 4
7 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4 Ketamine
8 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
9 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
10 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
11 Feasibility Study of Take-Home LAAM Medication Completed NCT00000300 Phase 4 LAAM
12 A Phase 4, Pilot, Open-label Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
13 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
14 A Single Center, Randomized, 2 Way Cross-Over, Phase 4 Study Comparing Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 Including Ease of Use, Taste Preference, Dissolution Time, Desire to Abuse, and Overall Acceptance In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets
15 A Multi-center, Open-Label, 24-Week, Follow-Up Study to Assess Safety, Efficacy, and Treatment Adherence For Maintenance Treatment of Opioid Dependence With OX219 Completed NCT01903005 Phase 4 Higher bioavailability BNX sublingual tablets
16 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
17 Project STRIDE2 - Seek/Test/Retain: PLWHA and Opioid Users in Washington, DC Completed NCT03583138 Phase 4 buprenorphine
18 Feasibility, Mechanism of Action and Potential Side Effects of Extended Release Depot Naltrexone in Opioid Dependent Patients Completed NCT01471145 Phase 4 Naltrexone
19 A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence Completed NCT00007527 Phase 4 naloxone;buprenorphine
20 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4 Placebo;Buprenorphine
21 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
22 On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings Completed NCT00317460 Phase 4
23 A Feasibility Study for Testing the Effects of Extended-release Naltrexone (Vivitrol) on Recidivism and Other Participant Outcomes in Drug Court Settings Completed NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone
24 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
25 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
26 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
27 Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia: Randomize Double Blind Clinical Trial Completed NCT02992938 Phase 4 Acetazolamide;Placebo Oral Tablet
28 Intensive Outpatient v. Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
29 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
30 Evaluation of Preference for a Buprenorphine-based Maintenance Therapy, After a Switch From Buprenorphine Alone (Subutex®) to the Buprenorphine/Naloxone Combination (Suboxone®), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone
31 VIVITROL® (Naltrexone for Extended Release Injectable Suspension (XR-NTX)) for Opioid Dependent Inmates Released From Prison Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
32 Attention Training for Opioid-maintained Cocaine Users Completed NCT01870882 Phase 4
33 An Open-Label Pilot Study of Desvenlafaxine for Opioid-Dependent Patients With Comorbid Depression Completed NCT02200406 Phase 4 Desvenlafaxine
34 A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery Completed NCT01374763 Phase 4 Oxycodone;Prolonged-release oxycodone/naloxone
35 Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial (BRAVO) Completed NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
36 CTN-0051: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment Completed NCT02032433 Phase 4 Extended-Release Naltrexone;Buprenorphine-Naloxone
37 Naltrexone: Consummatory Behaviors in Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
38 Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth Completed NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
39 An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence Completed NCT01047527 Phase 4 Transdermal nicotine patch
40 Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
41 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Treatment in Opioid Dependent Chronic Back Pain Patients Completed NCT01559454 Phase 4 Methadone;Buprenorphine/naloxone
42 Pain Control in the Nuss Procedure: A Prospective, Randomized Trial of Cryoanalgesia vs. Thoracic Epidural Completed NCT02721017 Phase 4 Thoracic epidural (ropivicaine, fentanyl)
43 Use of Liposomal Bupivacaine for Postoperative Pain Management After Arthroscopic Rotator Cuff Repair Completed NCT03149887 Phase 4 Liposomal bupivacaine;Placebo
44 Influence of Dexmedetomidine and Lidocaine on Opioid Consumption, Cognitive Function and Incidence of Neuropathic Pain in Laparoscopic Intestine Resection Completed NCT02616523 Phase 4 Dexmedetomidine;Lidocaine;Fentanyl
45 Gabapentin Regimens and Their Effects on Opioid Consumption Completed NCT03334903 Phase 4 Gabapentin
46 Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial Completed NCT02922985 Phase 4 Intravenous acetominophen;Ketorolac, intramuscular;Bupivacaine, subcutaneous;Normal saline
47 Houston Emergency Opioid Engagement System (HEROES) Recruiting NCT03396276 Phase 4 Suboxone
48 Long Acting Naltrexone for Opioid Addiction: the Importance of Mental, Physical and Societal Factors for Sustained Abstinence and Recovery Recruiting NCT03647774 Phase 4 Extended release naltrexone
49 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
50 A Randomized Clinical Trial of Single Dose Liposomal Bupivacaine Delivered Via VATS Intercostal Nerve Block vs. Continuous Bupivacaine Infusion Delivered Via Indwelling Subscapular Catheter After Surgical Stabilization of Rib Fractures Recruiting NCT03305666 Phase 4 Liposomal bupivacaine injection;Bupivacaine indwelling catheter

Search NIH Clinical Center for Opiate Dependence

Inferred drug relations via UMLS 71 / NDF-RT 50 :


CLONIDINE HCL PWDR
Clonidine Hydrochloride
Levomethadyl
Levomethadyl Acetate Hydrochloride
Methadone
Methadone Hydrochloride
nalmefene
Nalmefene hydrochloride
Naloxone Hydrochloride
Naltrexone
Naltrexone hydrochloride

Genetic Tests for Opiate Dependence

Anatomical Context for Opiate Dependence

MalaCards organs/tissues related to Opiate Dependence:

40
Brain, Testes, Pituitary, Liver, Amygdala, Bone, Skin

Publications for Opiate Dependence

Articles related to Opiate Dependence:

(show top 50) (show all 3388)
# Title Authors PMID Year
1
Functional impact of a single-nucleotide polymorphism in the OPRD1 promoter region. 54 61
20300121 2010
2
Shared mechanisms for opioid tolerance and a transition to chronic pain. 54 61
20357116 2010
3
Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. 54 61
19403243 2009
4
ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. 54 61
18424454 2008
5
Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches? 54 61
18193922 2008
6
Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. 54 61
17416470 2007
7
The opioid system in alcohol and drug dependence: family-based association study. 54 61
17503481 2007
8
Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. 54 61
16583408 2006
9
In-vitro and in-vivo characterization of a buprenorphine delivery system. 54 61
16536895 2006
10
A functional prodynorphin promoter polymorphism and opioid dependence. 54 61
16314761 2005
11
Novel exonic mu-opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence. 54 61
15558714 2005
12
A genetic association study of the mu opioid receptor and severe opioid dependence. 54 61
12960749 2003
13
Introducing a new recruitment approach to sample collection for genetic association studies in opioid dependence. 54 61
12648891 2003
14
D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. 54 61
12497624 2003
15
The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. 54 61
11054765 2000
16
The DRD2 gene in psychiatric and neurological disorders and its phenotypes. 54 61
11256581 2000
17
Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review. 54 61
10881203 2000
18
Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (OPRM1). 54 61
9756053 1998
19
Dopamine D3 receptor gene variants and substance abuse in schizophrenia. 54 61
9702743 1998
20
The role of glutamate in physical dependence on opioids. 54 61
9517399 1998
21
Glutamate in opioid dependence. 54 61
9365966 1997
22
Human pharmacology of the opioid neuropeptide dynorphin A(1-13). 54 61
9190848 1997
23
Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users. 61
31816368 2020
24
Sex differences in the relationship between anxiety sensitivity and opioid misuse among adults with chronic pain. 61
31704430 2020
25
Antenatal interventions based upon fetal surveillance of the daily opioid-exposed fetus: a descriptive analysis. 61
30078349 2020
26
Development of a Brief Patient-Administered Screening Tool for Prescription Opioid Dependence for Primary Care Settings. 61
31591644 2020
27
Commentary on Higgins et al. (2020): How are chronic pain, psychological distress and opioid dependence related? 61
31884702 2020
28
Differential Use of Narcotics in Total Hip Arthroplasty: A Comparative Matched Analysis Between Osteoarthritis and Femoral Neck Fracture. 61
31564525 2020
29
Correlates of indicators of potential extra-medical opioid use in people prescribed opioids for chronic non-cancer pain. 61
31841260 2020
30
Plastic Surgery Patient Expectations for Postoperative Opioid Prescriptions. 61
32039997 2020
31
Gender differences in prescription opioid use and misuse: Implications for men's health and the opioid epidemic. 61
31816359 2020
32
Acceptability of a primary care-based opioid and pain review service: a mixed-methods evaluation in England. 61
31594772 2020
33
Chronic opioid pretreatment potentiates the sensitization of fear learning by trauma. 61
31787748 2020
34
The effect of methadone on the hypothalamic pituitary gonadal axis and sexual function: A systematic review. 61
31901578 2020
35
Discrimination learning in oxycodone-treated nonhuman primates. 61
31816487 2020
36
Impact of Buprenorphine Dosage on the Occurrence of Relapses in Patients with Opioid Dependence. 61
31940657 2020
37
Adhesion Molecules as Potential Novel Biomarkers for Opioid Dependence. 61
31951160 2020
38
Opioid-Induced Adaptations of cAMP Dynamics in the Nucleus Accumbens. 61
31964511 2020
39
Pain Control in Breast Surgery: Survey of Current Practice and Recommendations for Optimizing Management-American Society of Breast Surgeons Opioid/Pain Control Workgroup. 61
31965373 2020
40
A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal. 61
31443104 2020
41
Maternal responsivity and oxytocin in opioid-dependent mothers. 61
31401811 2020
42
Factors associated with treatment retention in pregnant women with opioid use disorders prescribed methadone or electing non-pharmacological treatment. 61
31068095 2020
43
Trauma Severity in Early Childhood Correlates with Stress and Satiety Hormone Levels in a Pilot Cohort Receiving Diamorphine Maintenance Treatment. 61
31940647 2020
44
Preoperative Stellate Ganglion Block for Perioperative Pain in Lateralized Head and Neck Cancer: Preliminary Results. 61
31791223 2020
45
Kratom (Mitragyna speciosa): Friend or Foe? 61
31999896 2020
46
Case Series: Limited Opioid Withdrawal With Use of Transdermal Buprenorphine to Bridge to Sublingual Buprenorphine in Hospitalized Patients. 61
31626394 2020
47
Medications Development for Treatment of Opioid Use Disorder. 61
31932466 2020
48
Predicting high-risk opioid prescriptions before they are given. 61
31937665 2020
49
Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. 61
31986228 2020
50
Association between opioid analgesic therapy and initiation of buprenorphine management: An analysis of prescription drug monitoring program data. 61
31923197 2020

Variations for Opiate Dependence

Expression for Opiate Dependence

Search GEO for disease gene expression data for Opiate Dependence.

Pathways for Opiate Dependence

Pathways related to Opiate Dependence according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 POMC PDYN OPRM1 OPRL1 OPRK1 OPRD1
2
Show member pathways
13.37 POMC PDYN OPRM1 OPRL1 OPRK1 OPRD1
3
Show member pathways
12.59 TH FOS DRD3 DRD2 CREB1
4
Show member pathways
12.47 POMC OPRM1 IGF1 FOS CREB1
5 12.38 TPH1 TH POMC OPRM1 NGF CREB1
6 12.15 POMC FOS DRD2 CREB1
7 11.93 TPH1 TH SLC6A4 NGF CREB1
8 11.76 POMC OPRM1 OPRD1 FOS
9
Show member pathways
11.75 TH DRD3 DRD2
10
Show member pathways
11.73 TH PDYN FOS DRD2 CREB1
11 11.7 POMC FOS CREB1
12 11.64 POMC FOS CREB1
13 11.61 TH NGF IGF1
15 11.41 TH FOS CREB1
16 11.29 NGF IGF1 DRD2
17
Show member pathways
10.82 TH SLC6A4 DRD3 DRD2
18 10.56 TH POMC DRD2 ANKK1

GO Terms for Opiate Dependence

Cellular components related to Opiate Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 10 SLC6A4 OPRM1 OPRL1 OPRK1 OPRD1 DRD3
2 axon GO:0030424 9.8 TH OPRM1 NGF DRD2 CREB1
3 dendrite GO:0030425 9.63 TH PDYN OPRM1 NPFF NGF DRD2
4 perikaryon GO:0043204 9.62 TH OPRM1 NPFF DRD2
5 integral component of postsynaptic membrane GO:0099055 9.54 SLC6A4 OPRM1 DRD2
6 dopaminergic synapse GO:0098691 9.43 DRD3 DRD2
7 spine apparatus GO:0097444 9.26 OPRM1 OPRD1
8 integral component of presynaptic membrane GO:0099056 9.26 SLC6A4 OPRM1 OPRD1 DRD2
9 axon terminus GO:0043679 8.92 PDYN OPRD1 NPFF DRD2

Biological processes related to Opiate Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.31 POMC OPRM1 OPRL1 OPRK1 OPRD1 IGF1
2 G protein-coupled receptor signaling pathway GO:0007186 10.11 POMC PDYN OPRM1 OPRL1 OPRK1 OPRD1
3 cytokine-mediated signaling pathway GO:0019221 10.02 POMC OPRM1 OPRD1 FOS
4 response to hypoxia GO:0001666 9.96 TH SLC6A4 DRD2 CREB1
5 response to ethanol GO:0045471 9.89 TH OPRM1 DRD3 DRD2
6 circadian rhythm GO:0007623 9.87 TPH1 SLC6A4 CREB1
7 cellular response to growth factor stimulus GO:0071363 9.86 TH OPRD1 CREB1
8 response to toxic substance GO:0009636 9.86 SLC6A4 FOS DRD3 DRD2
9 excitatory postsynaptic potential GO:0060079 9.85 OPRM1 NPFF DRD2
10 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.85 OPRM1 OPRK1 OPRD1
11 sensory perception of pain GO:0019233 9.85 OPRM1 OPRL1 OPRK1
12 social behavior GO:0035176 9.84 TH SLC6A4 DRD3
13 memory GO:0007613 9.84 TH SLC6A4 NGF CREB1
14 visual learning GO:0008542 9.83 DRD3 DRD2 CREB1
15 response to nicotine GO:0035094 9.82 TH DRD2 CREB1
16 response to cocaine GO:0042220 9.8 OPRM1 DRD3 DRD2
17 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.8 OPRL1 DRD3 DRD2
18 response to amphetamine GO:0001975 9.79 TH DRD3 DRD2
19 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.78 OPRM1 OPRL1 OPRK1 OPRD1
20 response to light stimulus GO:0009416 9.76 TH FOS DRD2
21 negative regulation of blood pressure GO:0045776 9.75 OPRL1 DRD3 DRD2
22 response to growth factor GO:0070848 9.72 TH OPRM1
23 prepulse inhibition GO:0060134 9.72 DRD3 DRD2
24 response to immobilization stress GO:0035902 9.72 TPH1 TH FOS
25 locomotory behavior GO:0007626 9.72 TH OPRM1 OPRK1 DRD3 DRD2
26 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.71 DRD3 DRD2
27 dopamine metabolic process GO:0042417 9.71 DRD3 DRD2
28 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.71 DRD3 DRD2
29 neurotransmitter biosynthetic process GO:0042136 9.71 TH SLC6A4
30 positive regulation of renal sodium excretion GO:0035815 9.71 DRD3 DRD2
31 regulation of sensory perception of pain GO:0051930 9.71 OPRM1 OPRL1 OPRD1 NPFF
32 positive regulation of urine volume GO:0035810 9.7 OPRL1 DRD2
33 G protein-coupled receptor internalization GO:0002031 9.7 DRD3 DRD2
34 regulation of potassium ion transport GO:0043266 9.7 DRD3 DRD2
35 synaptic transmission, dopaminergic GO:0001963 9.7 TH DRD3 DRD2
36 response to drug GO:0042493 9.7 TH SLC6A4 NPFF FOS DRD3 DRD2
37 behavior GO:0007610 9.69 OPRL1 OPRK1
38 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.69 OPRM1 DRD3
39 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.69 DRD3 DRD2
40 negative regulation of voltage-gated calcium channel activity GO:1901386 9.69 OPRL1 DRD3 DRD2
41 aromatic amino acid family metabolic process GO:0009072 9.68 TPH1 TH
42 acute inflammatory response to antigenic stimulus GO:0002438 9.68 OPRM1 NPFF
43 negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0106072 9.67 OPRM1 OPRL1
44 behavioral response to ethanol GO:0048149 9.67 OPRM1 DRD3 DRD2
45 response to morphine GO:0043278 9.67 OPRM1 NPFF DRD3 DRD2
46 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.65 DRD3 DRD2
47 negative regulation of dopamine receptor signaling pathway GO:0060160 9.64 DRD3 DRD2
48 regulation of neurotransmitter uptake GO:0051580 9.63 DRD3 DRD2
49 regulation of locomotion involved in locomotory behavior GO:0090325 9.61 DRD3 DRD2
50 acid secretion GO:0046717 9.61 DRD3 DRD2

Molecular functions related to Opiate Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.91 OPRM1 OPRL1 OPRK1 OPRD1 DRD3 DRD2
2 peptide binding GO:0042277 9.46 OPRM1 OPRL1 OPRK1 OPRD1
3 dopamine binding GO:0035240 9.43 TH DRD3 DRD2
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.4 DRD3 DRD2
5 dopamine neurotransmitter receptor activity GO:0004952 9.37 DRD3 DRD2
6 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.32 TPH1 TH
7 neuropeptide binding GO:0042923 9.26 OPRM1 OPRL1 OPRK1 OPRD1
8 opioid receptor activity GO:0004985 8.92 OPRM1 OPRL1 OPRK1 OPRD1

Sources for Opiate Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....